Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Genomic and transcriptomic data have been generated across a wide range of prostate cancer (PCa) study cohorts. These data can be used to better characterize the molecular features associated with clinical outcomes and to test hypotheses across multiple, independent patient cohorts. In addition, derived features, such as estimates of cell composition, risk scores, and androgen receptor (AR) scores, can be used to develop novel hypotheses leveraging existing multi-omic datasets. The full potential of such data is yet to be realized as independent datasets exist in different repositories, have been processed using different pipelines, and derived and clinical features are often not provided or unstandardized. Here, we present the R package, a harmonized data resource representing >2900 primary tumor, >200 normal tissue, and >500 metastatic PCa samples across 19 datasets processed using standardized pipelines with updated gene annotations. We show that meta-analysis across harmonized studies has great potential for robust and clinically meaningful insights. is an open and accessible community resource with code made available for reproducibility.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882125PMC
http://dx.doi.org/10.1101/2023.01.17.524403DOI Listing

Publication Analysis

Top Keywords

prostate cancer
8
data resource
8
data
5
curatedpcadata integration
4
integration clinical
4
clinical genomic
4
genomic signature
4
features
4
signature features
4
features curated
4

Similar Publications

Background: With the advancement of MR-based imaging, prostate cancer ablative therapies have seen increased interest to reduce complications of prostate cancer treatment. Although less invasive, they do carry procedural risks, including rectal injury. To date, the medicolegal aspects of ablative therapy remain underexplored.

View Article and Find Full Text PDF

Background: Docetaxel is the most common chemotherapy regimen for several neoplasms, including advanced OSCC (Oral Squamous Cell Carcinoma). Unfortunately, chemoresistance leads to relapse and adverse disease outcomes.

Methods: We performed CRISPR-based kinome screening to identify potential players of Docetaxel resistance.

View Article and Find Full Text PDF

Effects of a Patient Decision Aid for Nonmetastatic Prostate Cancer Established in Routine Care: The Randomized Controlled EvEnt-PCA Trial.

Eur Urol Focus

September 2025

Department of Urology, Medical Centre, University of Heidelberg, Heidelberg, Germany; Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany; Department of Urology, Philipps-University Marburg, Marburg, Germany.

Background And Objective: Since 2016, >21 000 patients with prostate cancer (PC) used our personalized online decision aid in routine care in Germany. We analyzed the effects of this online decision aid for men with nonmetastatic PC in a randomized controlled trial.

Methods: In the randomized controlled EvEnt-PCA trial, 116 centers performed 1:1 allocation of 1115 patients with nonmetastatic PC to use an online decision aid (intervention = I) or a printed brochure (control = C).

View Article and Find Full Text PDF